article thumbnail

Dr. Eunice Brookman-Amissah: A Pioneer in Safe Abortion Law Reform

Bill of Health

She then served as Ghana’s Minister of Health from 1996 to 1998 and as Ghana’s Ambassador to the Netherlands from 1998 to 2001. From Minister to Advocate Dr. Brookman-Amissah returned to Ipas in 2001, where she served as Vice President for Africa until 2014.

Doctors 111
article thumbnail

What Has COVID Ever Done For Us? Here 9 Examples

HIT Consultant

From public health officials reporting the Covid outbreak to the World Health Organization (WHO), it took scientists only a fortnight to isolate the virus and figure out the full sequence of its genetic material. Gene-editing technologies. IvorIvor has been in candidate search for more than 30 years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary 3 | Monthly Update 2021

SQA

In addition, considering the fact that one marketing authorization application is submitted in accordance with Article 8(3) of Directive 2001/83/EC and the other marketing authorization application is submitted under an abridged procedure (e.g., World Health Organization (WHO).

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

ANVISA announced major updates to its Resolution of the Collegiate Board of Directors (RDC) 185/2001. Brazil’s ANVISA Announces Major Medical Device Registration Updates, 16 September 2022. The changes will serve to strengthen the country’s medical device registration regulations upon their effective date of 01 March 2023.

FDA 40
article thumbnail

Zantac Chronicles – Concluding Chapters in the MDL

Drug & Device Law

Fudging – using “like” − about whether he followed certain methodology (World Health Organization) or not. Applying the same sort of “internally inconsistent principles” common to all Zantac plaintiffs’ experts. Zantac , 2022 WL 17480906, at *152-53. at *167 (quoting Glastetter v. Novartis Pharmaceuticals Corp. , 3d 986, 991 (8th Cir.

FDA 59